Adenomyosis

IWBCA
Feb 5
27 min read

Updated: Feb 16

Adenomyosis occurs when tissue similar to the lining of the uterus grows into the muscular wall of the uterus. This process causes the uterine wall to thicken and the uterus to enlarge, sometimes to roughly double or triple its usual size. It is a significant cause of heavy or prolonged menstrual bleeding, severe cramping, pelvic pressure or pain, and pain with sex. Adenomyosis is a benign condition, but it can severely affect quality of life. Management often begins with medications that suppress or regulate menstrual cycles and relieve pain, and progresses to uterine-sparing procedures or hysterectomy when symptoms remain uncontrolled.

Overview

What is adenomyosis?

Adenomyosis (pronounced “add-en-o-my-OH-sis”) occurs when endometrium-like tissue grows deep within the uterine muscle. This tissue continues to respond to monthly hormonal fluctuations, so it can thicken, break down, and bleed with each menstrual cycle. Because the bleeding is trapped inside the muscle, it can trigger inflammation, swelling, and microscopic scarring over time, leaving the uterus enlarged, firm, and tender.

Common symptoms include very painful periods, heavy or prolonged bleeding that can include clots, pelvic or lower abdominal pain that can persist outside of menstruation, and pain with vaginal penetration. Some people also feel pelvic pressure or a sense of fullness. Adenomyosis can occur on its own or in association with fibroids or endometriosis. It is benign and does not become cancerous, but it is a major structural cause of abnormal uterine bleeding and chronic pelvic pain.

Management is especially important for people with pro-thrombotic conditions and blood-clotting disorders because adenomyosis can destabilize both sides of the equation. Heavy bleeding can drive iron deficiency and anemia, and it can also push people to skip anticoagulant doses or make abrupt medication changes, which can increase clot risk. At the same time, adenomyosis has been linked in some cases to a more pro-coagulant inflammatory state, and several common bleeding-control options require extra caution in people with higher baseline clot risk. A steady, well-matched plan can reduce flare cycles, prevent crisis-driven decisions, and support both bleeding control and clot prevention.

Prevalence

How common is adenomyosis?

Adenomyosis is likely far more common than current statistics suggest. Many women and other people with a uterus are not aware they have the condition, because it may cause no symptoms or symptoms that resemble fibroids, endometriosis, or other gynecologic conditions. Large insurance and registry databases that count only coded diagnoses have suggested clinically recognized rates around 1 percent of reproductive-age patients, but these figures capture only those who receive a formal diagnosis in systems that record it.

When researchers look directly at the uterus with imaging or examine uterine tissue under a microscope, adenomyosis is found much more often. Studies of hysterectomy specimens report adenomyosis in roughly 15 percent to 70 percent of uteri removed for noncancerous gynecologic problems, depending on how intensively the tissue is sampled and which microscopic criteria are used.

Prospective ultrasound studies in general gynecology clinics, in which patients are scanned regardless of suspected adenomyosis, have identified adenomyosis in approximately 20-30% of patients. These findings support the idea that adenomyosis is common and frequently goes undiagnosed in people who have not had surgery.

Researchers detect adenomyosis particularly often in people who:

Have had a procedure on their uterus, such as a cesarean birth, dilation and curettage, fibroid removal, endometrial ablation, or other uterine surgery.
Are in their 30s, 40s, or early 50s, especially those approaching menopause, when cumulative exposure to menstrual cycles, pregnancies, and uterine procedures has been higher.
Have had pregnancies and deliveries, which appear to be associated with a greater likelihood that adenomyosis will later be found on imaging or in surgical specimens.
Are being evaluated for infertility or recurrent pregnancy loss, where adenomyosis is identified more often than in the general population. Some studies report adenomyosis in about one quarter to one third of patients in infertility clinics.
Have coexisting conditions such as uterine fibroids or endometriosis, which frequently occur in the same uterus and can mask or mimic adenomyosis on both imaging and symptom review.
Are adolescents or young adults with severe menstrual pain, heavy menstrual bleeding, or both, especially when symptoms persist despite initial treatments. Recent imaging-based studies in adolescents and young adults with these symptoms have reported adenomyosis in approximately 15 percent to 30 percent of patients, and in some series, even higher.

Importantly, these patterns describe where adenomyosis has been identified most often in research; they do not define who can have the condition. Adenomyosis is increasingly recognized in adolescents, in people in their 20s and early 30s, in individuals who have never been pregnant, and in those who have never had uterine surgery, particularly when they report severe cramps, heavy bleeding, or chronic pelvic pain that is dismissed as “normal.” Limited access to gynecologic specialty care, differences in referral patterns, and underuse of advanced imaging all contribute to underdiagnosis, especially in communities that already experience barriers to reproductive healthcare. As awareness and noninvasive diagnostic tools, such as high-quality transvaginal ultrasound and MRI, continue to improve, the true prevalence of adenomyosis across age groups and populations is expected to be substantially higher than historical estimates based solely on hysterectomy specimens.

Symptoms

What are the signs of adenomyosis?

About 1 in 3 people with adenomyosis have no clear symptoms, and the condition is only found when imaging is done for another reason or when the uterus is examined after surgery. For the rest, symptoms usually develop gradually and often follow a pattern of menstrual cycles that become heavier, more painful, and more disruptive over time. Heavy menstrual bleeding, painful periods, pelvic pain, and reduced fertility are the most consistently reported problems in clinical series.

Common features include:

Painful Menstrual Cramps (Dysmenorrhea): Menstrual cramps are typically moderate to severe and often feel deeper and more intense than past periods. Pain can begin several days before bleeding starts, peak during the heaviest flow, and continue longer into the period than it previously did. People describe sharp, stabbing cramps layered over a deep, aching, or “pressure-like” pain in the pelvis that can radiate into the lower back, hips, groin, and inner thighs. During flares, it may be hard to stand upright, walk, or continue usual activities, and some people also have nausea, vomiting, diarrhea, or a feeling of being “drained” and unwell.
Heavy Menstrual Bleeding (Menorrhagia): Periods often become noticeably heavier and longer. This may look like soaking through pads or tampons in less than two hours, needing to use double protection, passing large clots, or bleeding for more than seven days. Many people describe sudden “flooding” episodes that are difficult to control. Heavy bleeding is the most common single symptom reported in adenomyosis cohorts and is a major reason people seek care.
Abnormal Menstruation: Cycles can shift from previously regular to shorter intervals (bleeding more often), longer or more prolonged periods, or spotting before or after the main flow. Some people develop unpredictable or irregular bleeding that does not match their prior pattern, including bleeding between periods, which can be alarming and disruptive.
Pelvic, Back, Hip, or Thigh Pain: Pelvic pain may no longer be confined to menstruation and can persist as a dull, constant ache or a feeling of heaviness and pressure in the lower abdomen. Because the uterus shares nerve pathways with the lower back and legs, uterine pain can “refer” or spread, producing aching or burning in the lower back, buttocks, hips, groin, or thighs, particularly during periods. Some people notice leg pain, numbness, or tingling that worsens around menstruation, which can reflect nerve irritation from an enlarged, inflamed uterus.
Chronic Pelvic Pain Between Periods: Over time, pain may persist even when there is no active bleeding. This can appear as a constant, low-grade pelvic ache or pressure that worsens with prolonged standing, physical activity, or just before menstruation. For some, adenomyosis contributes to chronic pelvic pain that lasts most days of the month and significantly limits mobility and daily functioning.
Painful Intercourse (Dyspareunia): Penetrative sex, especially deep penetration, can cause sharp or aching pelvic pain during or after intercourse. This pain is often worse in the days before and during a period, when the uterus is most tender and congested. The fear of triggering pain can lead people to avoid sex, which can strain intimate relationships and affect quality of life.
Bladder or Bowel Pressure Symptoms: An enlarged, tender uterus may compress the bladder or rectum. This may cause a frequent need to urinate, a sense of not emptying the bladder completely, discomfort with a full bladder, or a feeling of pressure or difficulty with bowel movements, particularly during menstruation. These symptoms often overlap with those from fibroids or endometriosis, which commonly coexist with adenomyosis.
Infertility or Difficulty Conceiving: Adenomyosis can be associated with reduced fertility and pregnancy complications, particularly in people who also have endometriosis or fibroids. The abnormal uterine muscle and lining environment may interfere with embryo implantation or early pregnancy development. Studies of infertile populations show a higher prevalence of adenomyosis than in the general population, underscoring its contribution to subfertility in some patients.
Enlarged Uterus and “Bulk” Symptoms: The uterus may become enlarged and feel firm or “boggy” on examination. Some people can feel or see a rounded fullness in the lower abdomen, often described as looking “a few months pregnant.” This bulk can cause pelvic pressure, a sensation of carrying extra weight in the lower abdomen, or discomfort when bending forward or wearing tight clothing.
Abdominal Bloating or Fullness (“Adenomyosis Belly”): Chronic inflammation and uterine enlargement can contribute to abdominal bloating, visible distension, and a constant sense of fullness or tightness in the lower abdomen, especially in the days leading up to and during a period. People may notice that their clothes fit differently at different points in the cycle, and they may feel “puffy” or swollen even without a marked change in weight.
Systemic and Quality-of-Life Affects: Heavy bleeding and chronic pain can lead to iron-deficiency anemia and exhaustion, with symptoms including fatigue, shortness of breath on exertion, headaches, dizziness, and feeling unusually cold. Persistent pain, sleep disruption, and a sense of being dismissed or not believed can contribute to anxiety, low mood, and social withdrawal. Many people with adenomyosis report missed work or school days, limitations in exercise, and a major impact on daily activities, even though the condition is medically classified as benign.

Causes

What causes adenomyosis?

Researchers do not yet have a single, proven explanation for why some people develop adenomyosis while others do not. Current evidence supports a combination of hormonal, mechanical, inflammatory, and immune mechanisms that act in concert over time. Adenomyosis is now regarded as an estrogen-dependent chronic inflammatory condition in which endometrium-like glands and stroma appear inside the uterine muscle and trigger thickening, scarring, and enlargement of the uterus.

One major theory focuses on repeated microscopic injury and repair at the junction between the endometrium and the myometrium (the uterine muscle). According to the “tissue injury and repair” model, strong uterine contractions, menstruation, pregnancy, childbirth, and procedures such as cesarean birth or curettage can disrupt this junctional zone. Over many cycles of damage and healing, glands and stroma from the lining can be pulled or pushed into the muscle layer, where they continue to respond to hormones and drive chronic inflammation. This concept links adenomyosis and endometriosis as related disorders that arise from similar uterine injury and repair processes.

A second mechanism proposes that some people are born with small clusters of endometrium-like cells embedded in the myometrium. These “misplaced” cells remain quiet until they are activated by reproductive hormones. Once activated, they proliferate, recruit immune cells, and stimulate the surrounding muscle to hypertrophy, which contributes to uterine enlargement and pain. Imaging and pathologic studies of the uterine junctional zone support the idea that subtle developmental differences in this region can predispose to adenomyosis later in life.

Hormones clearly shape how adenomyosis behaves. The disease is strongly estrogen-driven, with increased local estrogen production within the uterine wall, higher expression of estrogen receptors, and increased aromatase activity that converts androgens to estrogens within the lesion itself. At the same time, many adenomyosis lesions show “progesterone resistance,” with reduced expression or abnormal signaling of progesterone receptors. This imbalance allows estrogen-driven proliferation and inflammation to proceed with less of progesterone’s usual calming, stabilizing effect on the endometrium.

Inflammation and immune dysregulation are central features rather than minor side effects. Studies of uterine tissue and blood in people with adenomyosis show increased numbers of activated macrophages and other immune cells, higher levels of pro-inflammatory cytokines such as interleukin-6, interferon-gamma, and MCP-1, and reduced levels of anti-inflammatory mediators like interleukin-10. Some patients also have circulating autoantibodies and other signs of immune activation. These immune changes appear to promote epithelial-mesenchymal transition and migration of endometrial cells into the myometrium, sustain chronic inflammation in the uterine wall, and alter the environment for implantation and early pregnancy.

Genetic and environmental factors likely shape vulnerability. Adenomyosis frequently coexists with other estrogen-sensitive, inflammatory gynecologic conditions, especially endometriosis and uterine fibroids, suggesting shared pathways in tissue remodeling, hormone signaling, and immune response. Family clustering and shared genetic risk loci across adenomyosis, endometriosis, and leiomyomas support this connection.

There is also emerging evidence that adenomyosis is part of a broader network of inflammatory and autoimmune conditions. Population-based and clinic studies report higher rates of autoimmune thyroiditis, rheumatoid arthritis, and systemic lupus erythematosus in patients with adenomyosis, particularly in adolescents and in those who also have endometriosis. A recent analysis of systemic comorbidities found that people with adenomyosis plus endometriosis had significantly more autoimmune diseases and stress- and pain-related disorders than those with adenomyosis alone, which suggests that overlapping inflammatory and immune pathways may intensify when these conditions coexist.

Taken together, current data indicate that adenomyosis develops in a uterus that is repeatedly exposed to mechanical stress and micro-injury, in a hormonal environment that favors high local estrogen and relative progesterone resistance, and in an immune landscape that is tilted toward chronic inflammation. These same hormonal and immune disturbances are observed in several other inflammatory and autoimmune conditions, which explains why adenomyosis often co-occurs with endometriosis, fibroids, and a subset of systemic autoimmune diseases, even though a direct cause-and-effect relationship has not been fully established.

Risk Factors

What are the risk factors for this condition?

Research suggests that adenomyosis is associated with several clinical and reproductive factors; however, these associations do not imply that individuals with these features will develop the condition, nor do they exclude those without them. Large epidemiologic studies consistently link adenomyosis with increasing age across the reproductive life span, higher parity, and a history of uterine procedures, but the condition is also being identified in younger patients, in people who have never been pregnant, and in those without any prior uterine surgery.

Current evidence highlights the following factors that appear more frequently among people diagnosed with adenomyosis:

Age in the Later Reproductive Years: Adenomyosis is often diagnosed in people in their 30s, 40s, and early 50s, especially those seeking care for heavy menstrual bleeding or pelvic pain in the years leading up to menopause. Longer cumulative exposure to estrogen over time may partly explain this pattern, although imaging studies show that adenomyosis can also occur in younger adults.
Pregnancies and Childbirth: Having one or more pregnancies and deliveries is associated with a higher likelihood of adenomyosis. Pregnancy and postpartum remodeling of the uterus involve stretching, thinning, and repair of the uterine wall, which may make it easier for endometrium-like tissue to extend into the muscle layer and become embedded there. In some studies, people with at least one live birth had several-fold higher odds of adenomyosis compared with those who had never given birth.
Prior Uterine Procedures: A history of procedures such as cesarean birth, dilation and curettage (D&C), myomectomy (fibroid removal), endometrial ablation, or other uterine interventions is linked to increased adenomyosis risk. These procedures can create microscopic scars and disrupt the junction between the uterine lining and the myometrium, potentially promoting the ingrowth of endometrium-like tissue into the myometrium over time.
Coexisting Gynecologic Conditions: Adenomyosis frequently occurs in the same uterus as endometriosis and uterine fibroids. People with these conditions appear to have higher rates of adenomyosis than the general population, and overlapping symptoms can make it more difficult to distinguish the conditions. This clustering suggests shared hormonal and inflammatory pathways that increase the risk of adenomyosis co-occurring with other gynecologic disorders.
Hormonal and Metabolic Factors: Several studies have associated adenomyosis with higher lifetime estrogen exposure, including early menarche, shorter menstrual cycles, higher body mass index, and use of medications such as tamoxifen. Obesity, diabetes, and hypertension have also been reported more often among patients with adenomyosis, which may reflect overlapping metabolic and hormonal pathways that influence the uterine lining and muscle.
Family and Individual Reproductive History: Case-control and imaging-based studies suggest that adenomyosis can appear in people with infertility or recurrent pregnancy loss at rates higher than in the general population, and it may contribute to implantation difficulties or adverse pregnancy outcomes in a subset of patients. This does not mean that adenomyosis always causes infertility, but it underlines the importance of considering the condition in comprehensive reproductive evaluations.

Clinicians are now diagnosing adenomyosis more often in people in their 20s and 30s who present with severe menstrual pain, heavy menstrual bleeding, or chronic pelvic pain that does not respond well to first-line treatments. Improved access to high-quality transvaginal ultrasound and pelvic MRI, along with greater clinical awareness, is revealing adenomyosis in age groups and reproductive histories that were previously underrepresented in surgical series based only on hysterectomy specimens.

These risk factors describe patterns seen in research. They do not define who “can” or “should” have adenomyosis. People who are younger, who have never been pregnant, who have no prior uterine procedures, or who live in communities with limited access to gynecologic care can still have significant adenomyosis-related symptoms that deserve recognition, thorough evaluation, and treatment.

Complications

What are the complications of adenomyosis?

The symptoms of adenomyosis often intensify across the reproductive years until menopause unless they are effectively managed. Heavy menstrual bleeding can lead to iron deficiency anemia, in which the body does not have enough healthy, iron-rich red blood cells to carry oxygen to tissues. Anemia can cause pronounced fatigue, reduced exercise tolerance, shortness of breath with exertion, headaches, dizziness, difficulty concentrating, paleness, brittle nails, or feeling unusually cold. In severe cases, anemia may require iron infusions or blood transfusions before surgery or during acute bleeding episodes.

Chronic pelvic pain, severe menstrual cramps, and pain with intercourse can significantly disrupt daily functioning. These symptoms may limit participation in work, school, caregiving responsibilities, and physical activity and can interfere with sleep. Over time, unmanaged pain and unpredictable heavy bleeding are associated with higher rates of anxiety, depressed mood, sexual distress, and strain in intimate relationships. For some, the need to plan around heavy or sudden bleeding leads to social withdrawal and loss of confidence in public or work settings.

In a subset of people, adenomyosis contributes to reduced fertility or pregnancy complications, especially when it coexists with endometriosis or fibroids. Studies have associated adenomyosis with lower implantation and live birth rates in assisted reproduction, higher rates of early pregnancy loss, and increased risks such as preterm birth, hypertensive disorders of pregnancy, and postpartum hemorrhage. These associations are not seen in every individual, but they highlight the importance of recognizing adenomyosis in those with infertility or recurrent pregnancy loss so that care teams can tailor preconception counseling and pregnancy monitoring.

Although adenomyosis is classified as a benign condition, the combination of pain, bleeding, anemia, and reproductive concerns can substantially reduce quality of life. For many people, symptom relief requires a comprehensive plan that may include:

Medications to Reduce Bleeding and Pain: Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to lessen menstrual pain. Hormonal treatments such as combined oral contraceptive pills, progestin-only pills, levonorgestrel-releasing intrauterine systems, and other progestin therapies can meaningfully decrease menstrual blood loss and cramping and are among the most frequently used options to control symptoms.
Therapies That suppress or Modulate Hormones: In more severe or refractory cases, gonadotropin-releasing hormone (GnRH) agonists or antagonists and other hormone-modulating medications may be used for limited periods to shrink the uterus, reduce bleeding, and calm pain, often as a bridge to longer-term strategies or surgery.
Uterine-Sparing Procedures: For some patients who wish to preserve the uterus, procedures such as adenomyomectomy (surgical removal of focal adenomyosis), high-intensity focused ultrasound, or uterine artery embolization can reduce pain and bleeding by targeting the most affected areas of uterine muscle. Suitability depends on the pattern and extent of adenomyosis and reproductive goals.
Hysterectomy: When symptoms are severe, other treatments have not provided adequate relief, and childbearing is complete, removal of the uterus offers the most reliable, long-term resolution of adenomyosis-related bleeding and uterine pain. Decisions about hysterectomy are individualized and should incorporate the person’s values, preferences, overall health, and available alternatives.
Supportive Care and Management of Complications: Iron supplementation or infusion may be required to treat anemia. Pelvic floor physical therapy, sexual counseling, and mental health support can help address the secondary impact of chronic pain, dyspareunia, and long-term symptom burden.

Taken together, these approaches can significantly improve the quality of life for many people living with adenomyosis. The most effective strategy is usually a tailored combination of therapies that reflects symptom severity, age, life stage, reproductive plans, other health conditions, and personal preferences.

Cancer

Can adenomyosis become cancerous?

No. Adenomyosis itself does not transform into cancer and is not considered a precancerous condition. However, its symptoms can overlap with those of more serious problems, such as endometrial hyperplasia or uterine cancer. For this reason, heavy or abnormal uterine bleeding, new pelvic pain, or other concerning changes always warrant evaluation, so that adenomyosis can be distinguished from other causes and an appropriate treatment plan can be made.

Diagnosis and Testing

How is adenomyosis diagnosed?

Adenomyosis is diagnosed by combining a careful history, physical examination, and imaging, while ruling out other causes of heavy bleeding and pelvic pain. There is no single blood test that confirms the diagnosis of adenomyosis. Historically, the “gold standard” diagnosis was made only after hysterectomy when a pathologist could see endometrium-like tissue inside the uterine muscle. Today, transvaginal ultrasound and magnetic resonance imaging (MRI) allow many people to receive a presumptive diagnosis without surgery.

Healthcare providers often suspect adenomyosis based on your symptoms, your age, and reproductive history, and one or more of these evaluations:

Pelvic Exam: During a pelvic exam, your provider may find that the uterus feels larger than expected for your age, more rounded or “globular,” and mildly to markedly tender when touched. The uterus may feel firm or “boggy,” and the ovaries are usually normal unless there is also endometriosis or other pathology. These findings are not specific to adenomyosis but, together with symptoms, raise suspicion.
Transvaginal Ultrasound: A transvaginal ultrasound uses a thin probe in the vagina to generate detailed images of the uterus and other pelvic organs. In experienced hands, ultrasound can reveal several features suggestive of adenomyosis, including a heterogeneous (mottled) myometrium, small fluid-filled spaces called myometrial cysts, asymmetrical thickening of one side of the uterine wall, fan-shaped shadowing, and an indistinct or irregular junction between the lining and the muscle. Ultrasound also helps identify or exclude fibroids, ovarian cysts, and other conditions that can mimic adenomyosis. A routine ultrasound does not fully exclude adenomyosis, but a characteristic pattern can support the diagnosis without surgery.
Magnetic Resonance Imaging (MRI): Pelvic MRI provides higher contrast detail of the uterine wall and is useful when ultrasound findings are unclear, when symptoms are severe, or when surgery or uterine-sparing procedures are being planned. On MRI, adenomyosis often appears as thickening of the “junctional zone” (the inner layer of the myometrium) beyond about 12 millimeters, areas of low signal intensity with tiny high-signal foci, and small subendometrial or myometrial cysts. MRI helps distinguish adenomyosis from fibroids, map focal adenomyosis or adenomyomas, and assess how much of the uterine wall is involved.
Endometrial Sampling or Biopsy: Because adenomyosis is located in the uterine muscle, a biopsy of the uterine lining is usually normal and cannot reliably diagnose or exclude adenomyosis. A biopsy is used to rule out more serious conditions, such as endometrial hyperplasia or cancer, in people with abnormal bleeding. If the biopsy is normal and the imaging findings are consistent with adenomyosis, the combination supports a benign structural cause for symptoms.
Blood Tests and Additional Assessments: Blood tests may be used to screen for iron-deficiency anemia caused by heavy menstrual bleeding, to rule out pregnancy or infection, and occasionally to evaluate other hormonal or bleeding disorders. Some people with adenomyosis have mildly elevated markers such as CA-125, but these tests are nonspecific and are not used alone to diagnose the condition.

Diagnosis is often a process of pattern recognition and exclusion. Providers look for a consistent story: progressively painful and heavy cycles, a tender, enlarged uterus, typical imaging features, and no evidence of malignancy or other primary causes. For many patients, this combination is sufficient to make a confident working diagnosis and guide treatment without removing the uterus.

Management and Treatment

How is adenomyosis managed or treated?

Treatment is tailored to symptom severity, age, coexisting conditions, and whether you want to preserve fertility or keep your uterus. Adenomyosis is driven by estrogen, so symptoms often lessen after menopause. Until then, treatment focuses on controlling pain and bleeding, shrinking or stabilizing the disease where possible, and preserving fertility when desired.

Common options include:

Pain Medications: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen are often the first-line option for period-related pelvic pain because they block prostaglandins. Prostaglandins are the chemical messengers that increase uterine contractions and inflammation, which is why cramping pain can feel deep, tight, and progressive. By lowering prostaglandin activity, NSAIDs directly reduce the intensity of uterine contractions and the inflammatory component of pain. This is also why they tend to work better for true cramp-driven pain than many “period relief” combination products.

Timing and dosing strategy are relevant. NSAIDs are typically most effective when started one to two days before the expected period, then taken on a consistent schedule through the heaviest bleeding days. Starting early can blunt the prostaglandin surge that builds as bleeding begins. Taking them intermittently, after pain is already severe, often provides less relief.

Period-specific combination products, such as Midol, may still be useful for some individuals, but they are designed to treat the overall symptom cluster. Depending on the formulation, they may include acetaminophen for pain perception, caffeine for fatigue and headaches, and an antihistamine for irritability or fluid retention. These ingredients can help the overall “period experience,” but they usually do not suppress prostaglandins as directly as NSAIDs, which is the key mechanism for reducing uterine cramping.

NSAIDs do not treat the underlying adenomyosis, but they are often a valuable part of a broader management plan that may also include hormonal suppression, pelvic floor support, iron repletion when bleeding is heavy, and escalation to procedural options when symptoms remain uncontrolled.
Hormonal Medications: Hormonal therapies are the primary medical treatment because they thin the lining, reduce menstrual bleeding, and suppress the hormonal cycling that drives adenomyosis. Options include combined estrogen–progestin contraceptives (pills, patches, or rings), progestin-only pills, and long-acting progestin injections. These treatments can make periods lighter or stop them altogether, reduce cramping, and in some cases, modestly reduce uterine volume. They can be used cyclically or continuously, depending on goals and side effects.
Levonorgestrel-Releasing Intrauterine Device (IUD): A hormonal IUD that releases levonorgestrel (for example, a 52 mg device) places progestin directly inside the uterus. This often leads to substantial reductions in bleeding and pain and is one of the most studied treatments for adenomyosis. Many users experience much lighter periods or amenorrhea and improvement in anemia, with a relatively low systemic hormone dose. In some series, the IUD also reduces uterine size and the need for hysterectomy.
Nonhormonal Medication: Tranexamic acid is an antifibrinolytic medication used only on days of heavy bleeding. It facilitates blood clotting in the uterus, reducing menstrual blood loss without affecting hormone levels. It can be useful for people who cannot or do not wish to use hormonal therapy, although it does not address pain or disease progression.
GnRH Agonists and Antagonists: Gonadotropin-releasing hormone (GnRH) agonists and newer oral GnRH antagonists temporarily lower estrogen to very low levels, creating a reversible “medical menopause.” This often reduces pain, bleeding, and uterine volume and can be used as a short-term bridge to surgery or pregnancy. Because long-term use can cause bone loss and menopausal symptoms, these drugs are typically used for limited periods and sometimes combined with low-dose “add-back” hormones to protect bone and improve tolerability.
Uterine-Sparing Interventional Procedures: For people who prefer to avoid hysterectomy and whose symptoms persist despite medical therapy, several minimally invasive options may be considered in specialized centers:
- Uterine Artery Embolization (UAE): Tiny particles are injected through a catheter to block blood flow to adenomyotic tissue, causing it to shrink. UAE can significantly improve bleeding and pain in many patients, although some may need repeat treatment, and its impact on future pregnancy is still under study.
- High-Intensity Focused Ultrasound (HIFU): Focused ultrasound energy is used under imaging guidance to heat and destroy adenomyotic tissue without incisions. Early studies indicate improvements in pain, bleeding, and uterine volume, with generally favorable safety and potential for fertility preservation, although availability is limited and long-term data remain limited.
- Other Focused or Ablative Techniques: In selected cases, radiofrequency ablation or hysteroscopic approaches may be used to treat focal disease or superficial components, often as part of a broader plan.
Adenomyomectomy: In people with focal adenomyosis or adenomyomas who wish to preserve fertility, surgeons may remove the diseased portion of the uterine muscle and reconstruct the uterus. This procedure is technically demanding and carries risks, including uterine rupture in a future pregnancy, so it is generally reserved for carefully selected cases in centers with specific expertise. Symptom relief can be substantial, but recurrence is possible.
Hysterectomy: Removal of the uterus is the definitive surgical treatment for adenomyosis and reliably eliminates menstrual bleeding and uterine pain. It is usually considered when symptoms are severe, medical and less invasive options have failed or are not appropriate, and childbearing is complete. Ovaries can often be preserved to avoid immediate menopause. Hysterectomy ends the possibility of carrying a pregnancy in the future.

Supportive care is also important. Many patients benefit from iron supplementation for anemia, pelvic floor physical therapy for chronic pain and muscle guarding, and psychological or social support to address the impact of long-standing symptoms on daily life.

Iron and Nutrient Repletion

Why are iron and certain vitamins often affected in those with adenomyosis?

Heavy or prolonged menstrual bleeding can gradually deplete iron stores, leading to iron deficiency with or without anemia. Low iron reduces the blood’s ability to carry oxygen, which can worsen fatigue, shortness of breath with exertion, headaches, dizziness, paleness, and cognitive sluggishness. Iron deficiency can also cause symptoms even before anemia develops, particularly when ferritin, the body’s iron storage marker, is low.

Iron supplementation is often recommended when laboratory testing confirms deficiency. Oral iron is commonly used first, and absorption can be improved by taking it with vitamin C and separating it from calcium, antacids, and high-fiber meals. Some individuals need intravenous iron when oral iron causes significant gastrointestinal side effects, when deficiency is severe, or when ongoing bleeding outpaces oral repletion. Follow-up testing is typically used to confirm that hemoglobin and ferritin are recovering and to guide the duration of supplementation.

Other nutrient deficiencies can worsen fatigue, pain sensitivity, and recovery, particularly in the setting of chronic inflammation, dietary restriction, or coexisting gastrointestinal conditions. Vitamin B12 and folate are important for red blood cell production, and low levels can intensify fatigue and contribute to anemia-like symptoms even when iron is being addressed. Vitamin D deficiency is common and may amplify musculoskeletal pain and inflammatory signaling. Magnesium is sometimes used as a supportive measure for cramping and sleep quality, although responses vary. Correcting these deficiencies does not treat adenomyosis itself, but restoring iron stores and key micronutrients can meaningfully improve stamina, symptom tolerance, and overall quality of life as part of a broader management plan.

Evolving Research

Why do some physicians believe GLP-1 medications may improve adenomyosis symptoms?

The working hypothesis is that GLP-1 medications may alleviate symptoms of adenomyosis by modulating the hormonal, metabolic, inflammatory, and pain-processing environments in the body, even though they do not target the uterus directly. Adenomyosis is strongly influenced by estrogen and chronic inflammation. GLP-1 therapies promote weight loss and reduce visceral fat, which can lower estrogen produced by adipose tissue and stabilize menstrual bleeding patterns. At the same time, they improve insulin resistance and other features of metabolic dysfunction that are linked to heavier bleeding, more painful periods, and overlapping conditions such as endometriosis and fibroids.

Researchers are interested in this connection because the mechanisms of GLP-1 medications align with what is already known about the behavior of adenomyosis. GLP-1 receptors are present in the nervous system and on immune and vascular cells; therefore, these drugs may also dampen inflammatory signaling and reduce central pain sensitization that amplifies pelvic pain. As reports accumulate from patients who notice changes in bleeding, pain, and energy after starting GLP-1 therapy, investigators are designing studies to move from individual experiences and mechanistic reasoning to structured evidence. The aim is to identify which patients are most likely to benefit, which symptom clusters respond, and how GLP-1 medications can be used alongside existing hormonal and procedural treatments to improve quality of life for people living with adenomyosis.

Outlook and Prognosis

What can I expect if I have this condition?

The outlook for adenomyosis depends on how extensive the disease is, how severe your symptoms are, and whether you are still having menstrual cycles. For many people, targeted treatment can turn a debilitating condition into one that is manageable day to day.

With current medical options, most patients who have moderate or severe symptoms can achieve meaningful relief. Large observational studies and recent trials show that hormonal treatments such as the levonorgestrel-releasing intrauterine device (LNG-IUS) and oral progestins like dienogest substantially reduce menstrual bleeding, pain scores, and the need for hysterectomy for a high proportion of patients, with overall satisfaction rates often above 80 percent. Some comparative studies report that LNG-IUS can improve quality of life to a degree similar to hysterectomy, particularly in psychological and social domains, while preserving the uterus.

Interventional options such as uterine artery embolization, high-intensity focused ultrasound, and carefully selected adenomyomectomy or other fertility-sparing surgeries can further reduce symptoms and uterine size in patients who do not respond adequately to medication or who cannot tolerate long-term hormonal therapy. These procedures entail their own risks and recurrence rates, but they provide additional avenues for symptom control when conservative measures are insufficient.

Adenomyosis is estrogen-dependent, so symptoms typically lessen as you approach menopause and usually resolve once menstrual cycles cease. Multiple clinical sources and cohort studies confirm that heavy bleeding and cramping almost always improve after natural or surgical menopause, although the uterus may remain somewhat enlarged or bulky, and any coexisting conditions (such as pelvic floor dysfunction or endometriosis) can still cause symptoms.

Without treatment, adenomyosis can lead to progressively heavier periods, iron deficiency anemia, chronic pelvic and back pain, and significant impacts on work, school, relationships, and mental health. The overall prognosis is favorable with respect to life expectancy, but the effect on quality of life can be substantial. Early recognition, appropriate imaging, and a tailored treatment plan are central to improving long-term outcomes.

Pregnancy

How does adenomyosis affect pregnancy?

Adenomyosis does not prevent all pregnancies, but it is increasingly recognized as a factor that can complicate both conceiving and carrying a pregnancy, especially in people with diffuse disease or a markedly enlarged uterus.

In terms of fertility, several systematic reviews and meta-analyses have shown that adenomyosis is associated with lower pregnancy and live birth rates and higher miscarriage rates, particularly in patients undergoing in vitro fertilization (IVF) or other assisted reproductive technologies. These analyses report roughly a 20 to 30 percent relative reduction in clinical pregnancy and live birth rates and about a twofold increase in miscarriage compared with infertile patients without adenomyosis. The negative impact appears to be more pronounced when the uterus is significantly enlarged (for example, larger than the size expected at 8 weeks of pregnancy) or when adenomyosis is diffuse rather than focal.

Once pregnancy is established, large cohort studies and recent meta-analyses have found that people with adenomyosis have higher risks of certain obstetric complications, including:

Higher rates of miscarriage and early pregnancy loss.
Increased risk of preterm birth, particularly in those with diffuse disease or larger pre-pregnancy uterine volume.
Higher odds of hypertensive disorders of pregnancy, such as gestational hypertension and preeclampsia.
Increased rates of placenta previa and other placental location abnormalities, and a higher likelihood of cesarean delivery.

These risks are elevated at a population level, but do not mean that every person with adenomyosis will experience complications. Many patients with adenomyosis conceive and deliver healthy babies, particularly when the condition is recognized, symptoms are optimized before conception, and pregnancy is monitored as a higher risk.

Recent data suggest that fertility-sparing interventions and well-chosen hormonal regimens before assisted reproduction can improve reproductive outcomes for some patients, although these approaches must be individualized. Pre-pregnancy counseling with a specialist who understands adenomyosis, along with early referral to high-risk obstetrics once pregnancy is confirmed, can help plan surveillance and delivery in a way that minimizes risk.

Prevention

How can women prevent adenomyosis?

Because the exact cause of adenomyosis is not fully understood and likely involves a combination of hormonal, mechanical, genetic, and inflammatory factors over many years, there is currently no proven way to prevent it.

However, there are practical steps that may help limit the impact of the disease once it begins to develop:

Paying attention to changes in menstrual bleeding patterns or pain and seeking evaluation early if periods become progressively heavier, longer, or more painful.

Undergoing appropriate imaging and evaluation when symptoms are significant, so that adenomyosis and other causes (such as fibroids or endometrial pathology) are identified and treated promptly.
Working with your healthcare team to manage coexisting inflammatory gynecologic conditions, such as endometriosis or fibroids, which often travel together with adenomyosis and may amplify symptoms and risks.

At present, no medication, supplement, or lifestyle change has been shown in controlled studies to prevent the development of adenomyosis. Research is ongoing into how uterine injury, reproductive history, and systemic inflammatory or autoimmune conditions may contribute to risk.

Life After Diagnosis

When should patients seek care from a healthcare provider?

You should contact a healthcare provider if you experience any of the following, especially if these are new, worsening, or affecting your daily life:

Extremely heavy periods that involve soaking through pads or tampons in less than two hours, passing large clots, “flooding” episodes, or bleeding that lasts more than seven days.
Severely painful cramps or pelvic pain that interferes with work, school, sleep, or normal activities, or pain that is clearly worsening from one cycle to the next.
Painful intercourse, particularly deep pelvic pain during or after penetration, that makes you avoid sex or causes ongoing pelvic soreness.
A feeling of fullness, heaviness, or visible enlargement in your lower abdomen, especially if it is associated with pelvic pressure, back or thigh pain during periods, or changes in bladder or bowel habits.
Symptoms of anemia, such as fatigue, shortness of breath during routine activities, dizziness, headaches, pallor, or feeling unusually cold, may indicate significant blood loss from heavy periods.
Any positive pregnancy test accompanied by cramping, spotting, or bleeding, given the higher baseline risk of pregnancy complications in people with adenomyosis.

Prompt evaluation can help distinguish adenomyosis from other causes of abnormal bleeding and pelvic pain and allows earlier treatment, which can improve long-term quality of life and, when relevant, pregnancy outcomes.

Provider Communication

What questions should you ask your healthcare provider?

If you have adenomyosis or are being evaluated for it, it can be helpful to bring a written list of questions to your appointment. Examples include:

Why do you think adenomyosis is the best explanation for my symptoms, and could there be other conditions contributing to them?
What imaging or tests have been done, and what did they show about the type, extent, or location of adenomyosis in my uterus?
What is the best first-line treatment for me based on my age, symptoms, other health conditions, and goals for future fertility?
How long should I use a given medication or device (i.e., an IUD) before we determine whether it is effective?
Are there options that can reduce my bleeding and pain without affecting my ability to conceive in the future, and when should we consider referral to a fertility specialist?
If I am already trying to get pregnant or considering IVF or other assisted reproductive treatments, how might adenomyosis affect my chances, and what can we do to optimize outcomes?
What pregnancy-related risks are higher in people with adenomyosis, and how would those risks be monitored and managed if I became pregnant?
At what point would you recommend procedures such as uterine artery embolization, high-intensity focused ultrasound, adenomyomectomy, or hysterectomy, and what are the benefits and risks of each in my case?
How often should I follow up with you to reassess my symptoms, anemia status, and the effectiveness of my treatment plan?
Are there pelvic floor physical therapy, pain management, mental health, or support resources you recommend to help me cope with chronic symptoms?

Clear answers to these questions can help you understand the implications of adenomyosis for your long-term health, make informed decisions about treatment, and plan for pregnancy and menopause in ways that align with your priorities.

Access to Treatment

What happens if adenomyosis is left untreated?

If adenomyosis is left untreated and symptoms are significant, several problems can develop over time. Heavy menstrual bleeding can cause iron deficiency anemia, which leads to fatigue, shortness of breath with exertion, headaches, dizziness, and feeling unusually cold. Ongoing anemia can strain the cardiovascular system and reduce exercise tolerance.

Chronic pelvic and back pain, painful intercourse, and unpredictable bleeding can disrupt work, school, relationships, and sleep, and are frequently linked with anxiety, low mood, and reduced quality of life.

Adenomyosis is also associated with reduced fertility and higher rates of miscarriage and adverse pregnancy outcomes in some studies, particularly when the disease is diffuse or coexists with endometriosis. Research has shown increased risks of early pregnancy loss, preterm birth, hypertensive disorders of pregnancy, placenta previa or other placental malposition, postpartum hemorrhage, and low birth weight in people with adenomyosis compared with those without it. These are risk associations, not certainties, and many individuals with adenomyosis do conceive and have healthy pregnancies, especially with appropriate management.

Symptoms may remain stable in some people, worsen gradually in others, or improve after menopause when estrogen levels fall. Because the pattern is unpredictable, ongoing follow-up with a knowledgeable provider and timely treatment when symptoms affect health, fertility, or daily function are key to limiting long-term impact.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider regarding any questions you may have about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.